GSK and Kyowa Hakko Latest to Ink SE Asia Deals with DKSH

- Last updated on GMT

Related tags: Medicine, Pharmacology

GSK and Kyowa Hakko Latest to Ink SE Asia Deals with DKSH
In another contract with Big Pharma in Asia, DKSH has penned a contract sales deal with GlaxoSmithKline.

In order to support its sale of antibiotics in medical and trade channels in Hong Kong, Pharma Giant GlaxoSmithKline (GSK) has selected market expansion company DKSH to provide contract sales services in both private clinics and trade channel.

In a press release, Vice President of DKSH Healthcare, Hong Kong, Richard Holloway said the agreement helped GSK to “concentrate on its core competencies while minimizing cost.”

“Outsourcing is a global trend and will continue to be significant when pharmaceutical companies require expert support along the value chain,”​ he continued to add.

GSK has become the latest Big Pharma company to use DKSH to expand services in the Asian market. Bayer​ and Pfizer​ both signed recent deals in Cambodia for DKSH to provide services which include distribution, logistics, customs clearance and sales.

Last week, DKSH penned an agreement with Japanese life science company Kyowa Hakko Kirin to provide regulatory consulting and product registration services for new biotechnology drugs in Thailand.

Related topics: Markets & Regulations

Related news

Show more

Follow us

Products

View more

Webinars